The privately-owned UK pharmaceutical company, Funxional Therapeutics Ltd, has raised €10 million in a Series B funding to advance its lead, small molecule drug candidate into Phase 2 for inflammatory conditions including asthma. ---Subscribe to MedNous to access this article--- Company News Finance, Grants, Deals
